EB病毒疫苗的研究进展  

Research progress on the vaccine of Epstein-Barr virus

作　　者：姜紫莹 田先淑 谢楚 钟茜[1] 孙聪 曾木圣[1] JIANG ZiYing;TIAN XianShu;XIE Chu;ZHONG Qian;SUN Cong;ZENG Mu-Sheng(State Key Laboratory of Oncology in South China,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室,广东省鼻咽癌诊治研究重点实验室,广东省恶性肿瘤临床医学研究中心,中山大学肿瘤防治中心,广州510060

出　　处：《中国科学：生命科学》2024年第12期2408-2426,共19页Scientia Sinica(Vitae)

基　　金：国家自然科学基金(批准号:82030046);国家重点研发计划(批准号:2022YFC3400900);中国博士后科学基金(批准号:GZB20230886,2023M743998)资助。

摘　　要：EB病毒(Epstein-Barr virus,EBV)是一种双链DNA病毒,属于疱疹病毒属.作为人类发现的第一个致瘤病毒,EB病毒感染与多种血液及上皮细胞性肿瘤密切相关.因此,有效的EB病毒预防性和治疗性疫苗对于疾病的防治有着重要意义,但目前为止还没有一款EB病毒疫苗获批临床使用.新型冠状病毒感染的暴发给全球病毒防控带来挑战,但同时也促进了一系列疫苗创新设计的出现.无论是在疫苗抗原的选择,还是新型疫苗平台的研发方面,新冠疫苗的发展都为病毒疫苗研发工作提供了新的思路和方向.近几年EB病毒疫苗的研发在纳米颗粒疫苗、mRNA疫苗等方面获得了较大的发展,多种EB病毒疫苗进入了临床试验.因此,本文将基于疫苗抗原的选择、疫苗平台和佐剂的使用和疫苗评估系统三个方面对EB病毒疫苗的研究现状进行综述,并对未来该领域的发展进行展望.Epstein-Barr virus(EBV)is a human herpesvirus that infects the majority of the human population.As the first reported human oncogenic virus,EBV is associated with various hematological malignancies and epithelial cancers.Therefore,effective prophylactic and therapeutic vaccines are of great significance for the control of the EBV-related disease.However,there is no EBV vaccine that has been proved in clinical use to date.The outbreak of the COVID-19 pandemic has brought great challenges for global virus control,and thus boosting the innovation of virus vaccine design.The development of vaccine against SARS-CoV-2 has provided insights for current vaccine research,no matter in the aspect of target antigen selection or vaccine design platform.In recent years,progress has been made in EBV vaccine such as nanoparticle and mRNA vaccine,and several vaccines against EBV have entered clinical trials.In this article,we will provide a comprehensive review of the current status of EBV vaccine based on antigen selection,vaccine platform,formulation and evaluation system.Additionally,a prospective outlook on the future developments in this field will be presented.

关 键 词：EB病毒 疫苗 糖蛋白 佐剂 动物模型 

分 类 号：R392[医药卫生—免疫学]